Management of Etonogestrel Subdermal Implant-related Bleeding

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Mayo Clinic
Sponsor:
Information provided by (Responsible Party):
Petra M. Casey, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01658995
First received: August 2, 2012
Last updated: June 4, 2014
Last verified: June 2014
  Purpose

This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System.

The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.


Condition Intervention Phase
ESI-related Bleeding
Drug: Doxycycline
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Management of Etonogestrel Subdermal Implant-related Bleeding in US Women: a Prospective, Randomized, Placebo-controlled Trial.

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Efficacy and safety of Doxycycline compared to placebo for unacceptable bleeding [ Time Frame: 13 weeks post-randomization ] [ Designated as safety issue: Yes ]

    The efficacy of Doxycycline on ESI-related bleeding will be compared to placebo based on rates of unacceptable bleeding and weekly prospective symptom diary at 13 weeks post-randomization.

    Method continuation rate at 13 weeks post-randomization will be compared.

    Bleeding patterns will be quantified based on the PBLAC and WHO classification of clinically important bleeding patterns over each 13 week reference period.

    Incidence of additional symptoms including acne, headache, mood changes in the treatment groups will be compared to placebo at randomization and 13 weeks post-randomization based on the weekly prospective symptom diary.

    Interval to recurrence of unacceptable bleeding post-randomized treatment will be calculated.

    Rate of adverse events associated with medical treatment will be documented by prospective symptom diary and BMI calculation. These include headache, mood changes, acne and change in BMI.



Secondary Outcome Measures:
  • Patient Satisfaction [ Time Frame: Change from randomization to 13 weeks post-treatment ] [ Designated as safety issue: No ]

    Patient satisfaction with ESI will be assessed at randomization (pre-treatment)and will be compared to patient satisfaction assessed at 13 weeks following primary treatment with Doxycycline / placebo.

    For patients receiving secondary treatment with Doxycycline, satisfaction with ESI will be assessed again at 26 weeks post-randomized treatment.


  • Method Continuation rate [ Time Frame: 26 weeks post-randomization ] [ Designated as safety issue: No ]

    Method continuation rate at 26 weeks post-randomized treatment for patients with continued unacceptable bleeding after primary treatment who undergo secondary treatment with Doxycycline will be calculated Rate of ESI removal for bleeding between 13 and 26 weeks post randomization. Rate of ESI removal for reasons other than bleeding with enumeration of reasons for removal between 13 and 26 weeks post-randomization.

    Alternative contraception chosen in the event of ESI removal will be documented.



Estimated Enrollment: 350
Study Start Date: August 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Doxycycline
Doxycycline 100 mg oral capsules, twice daily for 10 days
Drug: Doxycycline
Doxycycline 100 mg oral capsules twice daily for 10 days
Other Name: Adoxa, Alodox, Avidoxy, Bio-Tab, Doryx, Doxy Lemmon, Doxy-Caps, Monodox, Morgidox, Ocudox, Oracea, Oraxyl, Periostat, Vibra-Tabs, Vibramycin
Placebo Comparator: Placebo
Placebo capsules, identical to oral Doxycycline 100 mg, twice daily for 10 days.
Drug: Placebo
Placebo, one capsule orally twice daily for 10 days
Other Name: Sugar pill

Detailed Description:

ESI is a long-acting reversible contraceptive. Though safety and efficacy have been established world wide, only about 1 % of women have been reported to use this method. Its use is limited by bleeding pattern changes which result in requests for early removal, most commonly within the first 8 months of use.

Women ages 18-51 years, choosing ESI and who meet eligibility criteria, will be offered enrollment in the study at the time of ESI insertion. Every effort will be made to insert Implanon on the same day as consent unless medically contraindicated. Prospective diaries will be completed starting on the date of ESI insertion. All participants will be contacted by study personnel 13 weeks after enrollment and queried as to the presence of unacceptable bleeding. Bleeding concerns will be objectively assessed using a modification of the Pictorial Blood Loss Assessment Chart (PBLAC).

Participants initiating contact with bleeding concerns at any time after 13 weeks post-ESI insertion will be offered treatment randomization at the time of contact. The basis for randomized treatment will be whether the bleeding is considered "unacceptable" to the participant. This is inherently subjective, but constitutes the basis for most removal requests. Participants that report unacceptable bleeding at 13 weeks post-ESI insertion, and those who call with bleeding concerns anytime after 13 weeks post-ESI insertion, will be randomized into one of two groups, Doxycycline or matching placebo.

Participants that do not report unacceptable bleeding will continue to complete diaries and may be eligible for randomized treatment if unacceptable bleeding develops.

  Eligibility

Ages Eligible for Study:   18 Years to 51 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Premenopausal women, aged 18-51 years
  • Expressed desire for compliance-independent contraception
  • No current pregnancy or anticipated desire for childbearing within 3 years of study enrollment and Implanon insertion
  • Agreement to participate in all study related procedures and evaluations as documented by a signed informed consent

Exclusion Criteria:

  • Current or prior use of Implanon
  • Current long-term use of Doxycycline for other indications
  • Known structural uterine abnormalities such as polyp, submucosal leiomyoma
  • Prior permanent sterilization or endometrial ablation
  • Pregnancy or desire for childbearing within 3 years
  • Contraindications to or intolerance of etonogestrel
  • Allergy to or intolerance of Doxycycline
  • Inability or unwillingness to complete study related procedures and evaluations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01658995

Contacts
Contact: Kristi L Allen, BSN, RN 507-293-3446 allen.kristi1@mayo.edu
Contact: Maureen A Lemens, BSN, RN 507-293-1487 lemens.maureen@mayo.edu

Locations
United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Kristi L Allen, BSN, RN    507-293-3446    allen.kristi1@mayo.edu   
Contact: Maureen A Lemens, BSN, RN    507-293-1487    lemens.maureen@mayo.edu   
Sponsors and Collaborators
Petra M. Casey
Investigators
Principal Investigator: Petra Casey, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Petra M. Casey, Associate Professor of Obstetrics - Gynecology, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01658995     History of Changes
Other Study ID Numbers: 11-008933
Study First Received: August 2, 2012
Last Updated: June 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Mayo Clinic:
Implanon
Etonogestrel subdermal implant
Nexplanon
Contraception
Irregular Bleeding
Menometrorrhagia

Additional relevant MeSH terms:
Hemorrhage
Pathologic Processes
3-keto-desogestrel
Doxycycline
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Contraceptive Agents
Contraceptive Agents, Female
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014